Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 35

Related Articles by Review for PubMed (Select 17551159)

1.

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Group.

N Engl J Med. 2007 Jul 5;357(1):28-38. Epub 2007 Jun 5.

2.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
3.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Review.

PMID:
18698014
4.

Cardiovascular risk and cardiometabolic protection: role of glitazones.

Petrazzi L, Grassi D, Polidoro L, D'Aurelio A, Croce G, Properzi G, Tiberti S, Desideri G, Ferri C.

J Nephrol. 2008 Nov-Dec;21(6):826-35. Review.

PMID:
19034866
5.

Rosiglitazone and cardiovascular risk.

Kaul S, Diamond GA.

Curr Atheroscler Rep. 2008 Oct;10(5):398-404. Review.

PMID:
18706281
6.

The safety of rosiglitazone in the treatment of type 2 diabetes.

Singh S, Loke YK.

Expert Opin Drug Saf. 2008 Sep;7(5):579-85. doi: 10.1517/14740338.7.5.579 . Review.

PMID:
18759710
7.

The cardiovascular safety of rosiglitazone.

Ajjan RA, Grant PJ.

Expert Opin Drug Saf. 2008 Jul;7(4):367-76. doi: 10.1517/14740338.7.4.367 . Review.

PMID:
18613801
8.

Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.

Loke YK, Kwok CS, Singh S.

BMJ. 2011 Mar 17;342:d1309. doi: 10.1136/bmj.d1309. Review.

9.

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

Nissen SE, Wolski K.

Arch Intern Med. 2010 Jul 26;170(14):1191-1201. doi: 10.1001/archinternmed.2010.207. Review.

PMID:
20656674
10.

Safety and efficacy of rosiglitazone in the elderly diabetic patient.

Viljoen A, Sinclair A.

Vasc Health Risk Manag. 2009;5(1):389-95. Review.

11.

Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes.

Home P.

Diabetes Technol Ther. 2012 Jun;14 Suppl 1:S33-42. doi: 10.1089/dia.2012.0007. Review.

PMID:
22650223
12.

Rosiglitazone for type 2 diabetes mellitus.

Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD006063. Review.

PMID:
17636824
13.

Treatment of type 2 diabetes: New clinical studies and effects of GLP-1 on macrovascular complications.

Lesven S, Gautier JF, Mar├ęchaud R.

Ann Endocrinol (Paris). 2010 Dec;71(6):505-10. doi: 10.1016/j.ando.2010.09.001. Epub 2010 Oct 27. Review. Erratum in: Ann Endocrinol (Paris). 2011 Feb;72(1):13.

PMID:
21030006
14.

Rosiglitazone, myocardial ischemic risk, and recent regulatory actions.

Bourg CA, Phillips BB.

Ann Pharmacother. 2012 Feb;46(2):282-9. doi: 10.1345/aph.1Q400. Epub 2012 Jan 31. Review.

PMID:
22298606
15.

Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review.

Wang AT, McCoy CP, Murad MH, Montori VM.

BMJ. 2010 Mar 18;340:c1344. doi: 10.1136/bmj.c1344. Review.

17.

Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies.

Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS.

Metabolism. 2013 Jul;62(7):922-34. doi: 10.1016/j.metabol.2013.01.014. Epub 2013 Feb 16. Review.

PMID:
23419783
18.

The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies.

Varas-Lorenzo C, Margulis AV, Pladevall M, Riera-Guardia N, Calingaert B, Hazell L, Romio S, Perez-Gutthann S.

BMC Cardiovasc Disord. 2014 Sep 26;14:129. doi: 10.1186/1471-2261-14-129. Review.

19.

Glitazones in chronic kidney disease: potential and concerns.

Bolignano D, Zoccali C.

Nutr Metab Cardiovasc Dis. 2012 Mar;22(3):167-75. doi: 10.1016/j.numecd.2011.11.005. Epub 2012 Feb 23. Review. Erratum in: Nutr Metab Cardiovasc Dis. 2013 Jan;23(1):75.

PMID:
22364889
20.

Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us?

Schernthaner G, Chilton RJ.

Diabetes Obes Metab. 2010 Dec;12(12):1023-35. doi: 10.1111/j.1463-1326.2010.01262.x. Review.

PMID:
20977573
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk